companies inhibitor-therapeutics-inc 
IP Law 360
SEPTEMBER 9, 2022
Shareholders of Inhibitor Therapeutics Inc. have agreed to settle their lawsuit against the Florida drug company's directors and controlling stockholder in exchange for a series of revised license agreements, debt and equity cancelation, and $14.25 million in cash.
Patently-O
NOVEMBER 29, 2023
In Allgenesis Biotherapeutics Inc. Cloudbreak Therapeutics, LLC , Case No. Specifically, nintedanib is one of the most powerful multikinase inhibitors for reducing corneal neovascularization, a principal cause of pterygium. Inter partes review is not unique. 22-1706 (Fed. 10,149,820 (the ‘820 patent).
Expert insights. Personalized for you.
52 
Let's personalize your content